Evofem Biosciences announces last patient enrolled for AMPREVENCE, the phase 2b sexually transmitted infections trial of Amphora
July 2019
Click for full info +Full Info:
Resource Type:
Citation:
(2019, April 23). Cision PR Newswire.
Health Risks(s):
- Chlamydia
- Gonorrhea
- Unintended Pregnancy
Product type(s):
- MPTs
- VaginalCream
Topic(s):
- MPTs
- Development
Region(s)
- Global
URL of resource: